Why is Novo Nordisk stock sliding today?
Novo Nordisk's stock fell 2.8% to DKK 278.2 after Morgan Stanley downgraded it to Underweight, citing concerns over semaglutide's patent cliff and subdued growth outlook. Morgan Stanley expects semaglutide to represent 59% of sales in 2031, with patent expirations impacting sales. HSBC raised its price target to DKK 320 but maintained a Hold rating. The stock had already declined 0.9% the prior session.
How this was made
The 30-second read
Why it matters
Analyst downgrade highlights structural growth concerns, potentially prompting short‑term sell pressure.
Market read
The downgrade is the primary catalyst for the stock's intraday slide, making the article relevant for short‑term traders.
What to watch
HSBC's modest price‑target raise and the ongoing share‑buyback program could provide support.
Background
Novo Nordisk is a leading diabetes and obesity drug maker, with semaglutide accounting for a large share of revenue.
Ticker impact
Morgan Stanley downgraded Novo Nordisk B to Underweight, citing a looming semaglutide patent cliff, causing the stock to fall 2.8% intraday.
Potential additional 2‑3% decline over the next few days if concerns persist.
Analyst downgrade with a lower target directly impacts investor sentiment and aligns with the observed price drop.
Market effects
The downgrade may pressure other European pharma stocks reliant on single blockbuster drugs.
European markets could see modest weakness in the healthcare sector.
Limited to pharma sector; no broad market effect.
Counterpoint
If Novo Nordisk can successfully launch next‑generation obesity drugs, the patent cliff impact may be overstated.
Key entities
- AnalystMorgan Stanley
Downgraded Novo Nordisk to Underweight.
- AnalystHSBC
Raised price target but kept Hold rating.
